Status:
COMPLETED
Study to Asses Efficacy of Intralymphatic Immunotherapy
Lead Sponsor:
Rigshospitalet, Denmark
Collaborating Sponsors:
TRYG Foundation
Conditions:
Allergy
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of the study is to try a new route for specific immunotherapy (SIT). The current treatment form for SIT is subcutaneously (SCIT), which is a long treatment with up to 50 injections subcuta...
Eligibility Criteria
Inclusion
- grass pollen allergy through at least 2 seasons
- positive skin prick test
- positive Specific IgE of at least 2. (CAP)
- Signed informed consent
- for females a negative pregnancy test.
Exclusion
- out of age limits
- rhinoconjunctivitis all year round.
- uncontrolled seasonal asthma
- patients treated with steroids continuously or beta-blockers.
- pregnancy and breastfeeding
- HIV, Hepatitis B+c, and other immunological diseases.
- psychiatric disease
- treatment with SCIT or SLIT within the last 5 years
- participation in other clinical trials within the last 3 months.
Key Trial Info
Start Date :
July 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2012
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT01166269
Start Date
July 1 2010
End Date
November 1 2012
Last Update
November 8 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dermato-allergological dept. K
Gentofte Municipality, Hellerup, Denmark, 2900